Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Factors associated with oncologist discussions of the costs of genomic testing and related treatments.

Yabroff KR, Zhao J, de Moor JS, Sineshaw HM, Freedman AN, Zheng Z, Han X, Rai A, Klabunde CN.

J Natl Cancer Inst. 2019 Nov 1. pii: djz173. doi: 10.1093/jnci/djz173. [Epub ahead of print]

PMID:
31675070
2.

Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer.

Bradley MC, Zhou Y, Freedman AN, Yood MU, Quesenbery CP, Haque R, Van Den Eeden SK, Cassidy-Bushrow AE, Aaronson D, Potosky AL.

Cancer Causes Control. 2018 Aug;29(8):785-791. doi: 10.1007/s10552-018-1050-z. Epub 2018 Jun 29.

3.

Connections between pharmacoepidemiology and cancer biology: designing biologically relevant studies of cancer outcomes.

Rivera DR, McGlynn KA, Freedman AN.

Ann Epidemiol. 2016 Nov;26(11):741-745. doi: 10.1016/j.annepidem.2016.10.001. Epub 2016 Oct 15. No abstract available.

4.

Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety.

Pinheiro SP, Rivera DR, Graham DJ, Freedman AN, Major JM, Penberthy L, Levenson M, Bradley MC, Wong HL, Ouellet-Hellstrom R.

Ann Epidemiol. 2016 Nov;26(11):735-740. doi: 10.1016/j.annepidem.2016.04.012. Epub 2016 Aug 31. Review.

5.

Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Bradley MC, Black A, Freedman AN, Barron TI.

Cancer. 2016 Jul 1;122(13):2067-75. doi: 10.1002/cncr.30004. Epub 2016 May 3.

6.

Dosing recommendations for pharmacogenetic interactions related to drug metabolism.

Filipski KK, Pacanowski MA, Ramamoorthy A, Feero WG, Freedman AN.

Pharmacogenet Genomics. 2016 Jul;26(7):334-9. doi: 10.1097/FPC.0000000000000220.

PMID:
27058883
7.

Implementation of the 21-gene recurrence score test in the United States in 2011.

Lynch JA, Berse B, Petkov V, Filipski K, Zhou Y, Khoury MJ, Hassett M, Freedman AN.

Genet Med. 2016 Oct;18(10):982-90. doi: 10.1038/gim.2015.218. Epub 2016 Feb 11.

PMID:
26890451
8.

A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy.

Marrone M, Potosky AL, Penson D, Freedman AN.

PLoS Curr. 2015 Nov 17;7. pii: ecurrents.eogt.761b81608129ed61b0b48d42c04f92a4. doi: 10.1371/currents.eogt.761b81608129ed61b0b48d42c04f92a4.

9.

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.

Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, Atkins MB, Freedman AN, Minasian L, Potosky AL.

Cancer. 2016 Jan 1;122(1):124-30. doi: 10.1002/cncr.29728. Epub 2015 Oct 6.

10.

Effects of personalized colorectal cancer risk information on laypersons' interest in colorectal cancer screening: The importance of individual differences.

Han PK, Duarte CW, Daggett S, Siewers A, Killam B, Smith KA, Freedman AN.

Patient Educ Couns. 2015 Oct;98(10):1280-6. doi: 10.1016/j.pec.2015.07.010. Epub 2015 Jul 19.

11.

Targeted Cancer Screening in Average-Risk Individuals.

Marcus PM, Freedman AN, Khoury MJ.

Am J Prev Med. 2015 Nov;49(5):765-771. doi: 10.1016/j.amepre.2015.04.030. Epub 2015 Jul 10. Review.

12.

Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology.

Marrone M, Schilsky RL, Liu G, Khoury MJ, Freedman AN.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):484-9. doi: 10.1158/1055-9965.EPI-14-1086.

13.

Are we ready to predict late effects? A systematic review of clinically useful prediction models.

Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, Goodman KA, Johansen C, Matasar MJ, de Nully Brown P, Oeffinger KC, Vickers AJ.

Eur J Cancer. 2015 Apr;51(6):758-66. doi: 10.1016/j.ejca.2015.02.002. Epub 2015 Feb 27. Review.

14.

Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature.

Wu JW, Boudreau DM, Park Y, Simonds NI, Freedman AN.

Expert Opin Drug Saf. 2014 Aug;13(8):1071-99. doi: 10.1517/14740338.2014.926887. Epub 2014 Jul 5. Review.

PMID:
24999107
15.

Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies.

Marrone M, Filipski KK, Gillanders EM, Schully SD, Freedman AN.

PLoS Curr. 2014 May 27;6. pii: ecurrents.eogt.aa5415d435fc886145bd7137a280a971. doi: 10.1371/currents.eogt.aa5415d435fc886145bd7137a280a971.

16.

Pharmacogenomics in oncology care.

Filipski KK, Mechanic LE, Long R, Freedman AN.

Front Genet. 2014 Apr 8;5:73. doi: 10.3389/fgene.2014.00073. eCollection 2014. Review.

17.

Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.

Tsai HT, Isaacs C, Fu AZ, Warren JL, Freedman AN, Barac A, Huang CY, Potosky AL.

Breast Cancer Res Treat. 2014 Feb;144(1):163-70. doi: 10.1007/s10549-014-2836-7. Epub 2014 Jan 28.

18.

Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses.

Ioannidis JP, Zhou Y, Chang CQ, Schully SD, Khoury MJ, Freedman AN.

Ann Oncol. 2014 Jan;25(1):16-23. doi: 10.1093/annonc/mdt372. Epub 2013 Dec 4. Review.

19.

Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy.

Fu AZ, Tsai HT, Marshall JL, Freedman AN, Potosky AL.

J Oncol Pharm Pract. 2014 Oct;20(5):332-40. doi: 10.1177/1078155213507010. Epub 2013 Oct 11.

20.

Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population.

Zhou Y, Boudreau DM, Freedman AN.

Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43-50. doi: 10.1002/pds.3463. Epub 2013 May 30.

PMID:
23723142
21.

Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.

Simonds NI, Khoury MJ, Schully SD, Armstrong K, Cohn WF, Fenstermacher DA, Ginsburg GS, Goddard KA, Knaus WA, Lyman GH, Ramsey SD, Xu J, Freedman AN.

J Natl Cancer Inst. 2013 Jul 3;105(13):929-36. doi: 10.1093/jnci/djt108. Epub 2013 May 9.

22.

Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.

Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ, Sansbury LB, Potosky AL.

Ann Oncol. 2013 Jun;24(6):1574-9. doi: 10.1093/annonc/mdt019. Epub 2013 Feb 20.

23.

Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, Cerhan JR, Hartge P, Heist RS, Kushi LH, Lash TL, Morton LM, Onel K, Pierce JP, Robison LL, Rowland JH, Schrag D, Sellers TA, Seminara D, Shu XO, Thomas NE, Ulrich CM, Freedman AN.

J Natl Cancer Inst. 2013 Jan 16;105(2):85-94. doi: 10.1093/jnci/djs473. Epub 2012 Nov 28. Review.

24.

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team.

J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305. doi: 10.1093/jnci/djs317.

25.

Frontiers in cancer epidemiology: a challenge to the research community from the Epidemiology and Genomics Research Program at the National Cancer Institute.

Khoury MJ, Freedman AN, Gillanders EM, Harvey CE, Kaefer C, Reid BC, Rogers S, Schully SD, Seminara D, Verma M.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):999-1001. doi: 10.1158/1055-9965.EPI-12-0525. Epub 2012 Jun 4.

26.

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.

Waters EA, McNeel TS, Stevens WM, Freedman AN.

Breast Cancer Res Treat. 2012 Jul;134(2):875-80. doi: 10.1007/s10549-012-2089-2. Epub 2012 May 24.

27.

Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.

Shamloo BK, Chhabra P, Freedman AN, Potosky A, Malin J, Weiss Smith S.

Drug Saf. 2012 Jun 1;35(6):507-18. doi: 10.2165/11597600-000000000-00000.

PMID:
22612854
28.

Epidemiology--found in translation.

Spitz MR, Caporaso NE, Freedman AN.

Cancer Discov. 2011 Jun;1(1):21-2. doi: 10.1158/2159-8274.CD-11-0042. Epub 2011 Jun 1.

29.

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.

Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, Schully SD, Ramsey S, Tunis S, Freedman AN, Khoury MJ, Veenstra DL.

Genet Med. 2012 Jul;14(7):633-42. Review.

30.

Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century.

Khoury MJ, Clauser SB, Freedman AN, Gillanders EM, Glasgow RE, Klein WM, Schully SD.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2105-14. doi: 10.1158/1055-9965.EPI-11-0481. Epub 2011 Jul 27. Review.

31.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W.

J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Epub 2011 May 2. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

32.

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.

Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.

Eur J Clin Invest. 2011 Sep;41(9):1010-35. doi: 10.1111/j.1365-2362.2011.02493.x. Epub 2011 Mar 15.

PMID:
21434890
33.

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.

Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.

Eur J Epidemiol. 2011 Apr;26(4):313-37. doi: 10.1007/s10654-011-9551-z.

34.

Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration.

Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.

J Clin Epidemiol. 2011 Aug;64(8):e1-e22. doi: 10.1016/j.jclinepi.2011.02.003. Epub 2011 Mar 16.

PMID:
21414753
35.

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.

Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ.

Eur J Hum Genet. 2011 May;19(5):18 p preceding 494. doi: 10.1038/ejhg.2011.27.

36.

Representing randomness in the communication of individualized cancer risk estimates: effects on cancer risk perceptions, worry, and subjective uncertainty about risk.

Han PK, Klein WM, Killam B, Lehman T, Massett H, Freedman AN.

Patient Educ Couns. 2012 Jan;86(1):106-13. doi: 10.1016/j.pec.2011.01.033. Epub 2011 Mar 5.

37.

Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations.

van Zitteren M, van der Net JB, Kundu S, Freedman AN, van Duijn CM, Janssens AC.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):9-22. doi: 10.1158/1055-9965.EPI-10-0329. Review.

38.

Correlates of unrealistic risk beliefs in a nationally representative sample.

Waters EA, Klein WM, Moser RP, Yu M, Waldron WR, McNeel TS, Freedman AN.

J Behav Med. 2011 Jun;34(3):225-35. doi: 10.1007/s10865-010-9303-7. Epub 2010 Nov 26.

39.

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.

J Natl Cancer Inst. 2010 Nov 17;102(22):1698-705. doi: 10.1093/jnci/djq390. Epub 2010 Oct 13.

40.

Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey.

Scheuner MT, McNeel TS, Freedman AN.

Genet Med. 2010 Nov;12(11):726-35. doi: 10.1097/GIM.0b013e3181f30e9e.

PMID:
20921897
41.

Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening.

Graubard BI, Freedman AN, Gail MH.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2430-6. doi: 10.1158/1055-9965.EPI-10-0324. Epub 2010 Sep 14.

42.

Communication of uncertainty regarding individualized cancer risk estimates: effects and influential factors.

Han PK, Klein WM, Lehman T, Killam B, Massett H, Freedman AN.

Med Decis Making. 2011 Mar-Apr;31(2):354-66. doi: 10.1177/0272989X10371830. Epub 2010 Jul 29.

43.

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.

Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):443-6. doi: 10.1158/1055-9965.EPI-09-0930.

44.

The impact of changes in hormone therapy on breast cancer incidence in the US population.

Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J.

Cancer Causes Control. 2010 Jan;21(1):83-90. doi: 10.1007/s10552-009-9437-5. Epub 2009 Oct 1.

PMID:
19795215
45.

Laypersons' responses to the communication of uncertainty regarding cancer risk estimates.

Han PK, Klein WM, Lehman TC, Massett H, Lee SC, Freedman AN.

Med Decis Making. 2009 May-Jun;29(3):391-403. doi: 10.1177/0272989X08327396. Epub 2009 May 21.

46.

Conceptual problems in laypersons' understanding of individualized cancer risk: a qualitative study.

Han PK, Lehman TC, Massett H, Lee SJ, Klein WM, Freedman AN.

Health Expect. 2009 Mar;12(1):4-17. doi: 10.1111/j.1369-7625.2008.00524.x.

47.

Colorectal cancer risk prediction tool for white men and women without known susceptibility.

Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, Pee D, Gail MH, Pfeiffer RM.

J Clin Oncol. 2009 Feb 10;27(5):686-93. doi: 10.1200/JCO.2008.17.4797. Epub 2008 Dec 29.

48.

Validation of a colorectal cancer risk prediction model among white patients age 50 years and older.

Park Y, Freedman AN, Gail MH, Pee D, Hollenbeck A, Schatzkin A, Pfeiffer RM.

J Clin Oncol. 2009 Feb 10;27(5):694-8. doi: 10.1200/JCO.2008.17.4813. Epub 2008 Dec 29.

49.

The relation between projected breast cancer risk, perceived cancer risk, and mammography use. Results from the National Health Interview Survey.

Gross CP, Filardo G, Singh HS, Freedman AN, Farrell MH.

J Gen Intern Med. 2006 Feb;21(2):158-64. Epub 2005 Dec 22.

50.

Cancer risk prediction models: a workshop on development, evaluation, and application.

Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM.

J Natl Cancer Inst. 2005 May 18;97(10):715-23.

PMID:
15900041

Supplemental Content

Loading ...
Support Center